CARGO Therapeutics (CRGX) Stock Price, News & Analysis

Company Overview

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Key Stats

• Today's Range: $4.39 to $4.57
• 50-Day Range: $3.42 to $4.55
• 52-Week Range: $3.00 to $25.45
• Volume: 580,974 shs
• Average Volume: 478,238 shs
• Market Capitalization: $209.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Reduce

CARGO Therapeutics Stock Analysis - MarketRank™

CARGO Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 417th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Reduce

Consensus Rating

CARGO Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CARGO Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CARGO Therapeutics are expected to grow in the coming year, from ($3.69) to ($2.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CARGO Therapeutics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CARGO Therapeutics is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CARGO Therapeutics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CRGX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CARGO Therapeutics does not currently pay a dividend.

Dividend Growth

CARGO Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CRGX.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.16

News Sentiment

CARGO Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for CARGO Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CARGO Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.38% of the stock of CARGO Therapeutics is held by insiders.

Percentage Held by Institutions

93.16% of the stock of CARGO Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRGX Stock Analysis - Frequently Asked Questions

How have CRGX shares performed this year?

CARGO Therapeutics' stock was trading at $14.42 on January 1st, 2025. Since then, CRGX shares have decreased by 68.4% and is now trading at $4.55.
View the best growth stocks for 2025 here.

How were CARGO Therapeutics' earnings last quarter?

CARGO Therapeutics, Inc. (NASDAQ:CRGX) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($1.14) by $0.26.

When did CARGO Therapeutics IPO?

CARGO Therapeutics (CRGX) raised $281 million in an initial public offering (IPO) on Friday, November 10th 2023. The company issued 18,750,000 shares at $15.00 per share.

Who are CARGO Therapeutics' major shareholders?

Top institutional investors of CARGO Therapeutics include Rhumbline Advisers (0.10%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Perceptive Advisors Llc, Gina Chapman and Anup Radhakrishnan.
View institutional ownership trends.

How do I buy shares of CARGO Therapeutics?

Shares of CRGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CARGO Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CARGO Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 4/15/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRGX
• Previous Symbol: NASDAQ:CRGX
• CIK: 1966494
• Web: cargo-tx.com
• Phone: 650-379-6143
• Fax: N/A
• Employees: 116
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $33.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +229.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-98,150,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.16%
• Return on Assets: -33.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.94
• Quick Ratio: 18.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.84 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 46,052,000
• Free Float: 45,393,000
• Market Cap: $209.54 million
• Optionable: N/A
• Beta: 0.66